Director appointment

MedaPhor Group plc (AIM: MED), the global provider of advanced ultrasound skills training simulators for medical professionals, announces the appointment of Ian Whittaker as Chief Operating Officer and Executive Director, effective as of 21 September 2016. Ian George Whittaker, aged 62, was formerly the CEO of Inventive Medical Ltd (“IML”), the cardio ultrasound simulation company that was acquired by MedaPhor in August 2016. Ian previously held roles at Hewlett Packard, where he was appointed to the UK Board in 2002, working as Vice President for the UK Consumer, Imaging and Printing team. Since leaving Hewlett Packard in 2005, Ian worked for [...]

September 22nd, 2016|

MedaPhor announces launch of new ScanExaminer simulator

MedaPhor Group plc (AIM:MED) (‘MedaPhor’) announces today the launch of ScanExaminer, a new ultrasound skills examination simulator for hospitals and examination bodies to exam a medical professional’s ultrasound skills. The system’s unique combination of real feel probe manipulation in all scanning planes and ultrasound sweeps based on real patient scans, that have been compiled using MedaPhor’s unique simulation of real patient scans, enables hospitals and external examination bodies to truly test a physician’s ultrasound image interpretation and probe manipulation skills. Unlike medical training simulators, ScanExaminer removes all training aids and functions (curriculum based learning modules, cut-away anatomy, probe guidance, recorded expert playback, [...]

September 8th, 2016|

Notice of material contract change

MedaPhor Group plc (AIM: MED), the global provider of advanced ultrasound skills training simulators for medical professionals, announces that the American Board of Obstetrics and Gynecology (ABOG) has served notice on the Company to terminate its contract with MedaPhor. The directors believe that MedaPhor’s business relationship with ABOG is a good one and can be resurrected. The ABOG has apprised MedaPhor that, if the patent infringement action which was announced by the Company on 27 April 2016 is resolved in a manner that is satisfactory to the ABOG, and there are no other threats to MedaPhor’s ability to market, sell [...]

September 8th, 2016|